Q BIOMED (QBIO) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 2 78 sessions, March 19, 2025 to March 25, 2026
- Largest daily move
- +100% close of March 26, 2025
- 1-year change
- +0% closing prices, March 19, 2025 to March 25, 2026
- 1-month change
- +0% closing prices, February 18, 2026 to March 25, 2026
Company Description
Q BIOMED (OTC: QBIO) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $14.5K.
QBIO has gained 0.0% over the past year. The last closing price was $0.0001.
For FY2022, Q BIOMED reported revenue of $284K with net income of -$2.1M and diluted earnings per share of -$0.08. The company operates at a net profit margin of -721.7%.
This page collects what Stock Titan holds for QBIO, including price data, latest news, and financial highlights.
Stock Performance
Q BIOMED (QBIO) closed at $0.0001 on March 25, 2026. Over the past 12 months, the price has gained 0.0%.
QBIO Metrics & Rankings
Price returns through March 25, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Q BIOMED has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial. View all QBIO news →
SEC Filings
Financial Highlights
Q BIOMED generated $284K in revenue in FY2022, retaining a -3.2% gross margin, operating income reached -$3.4M (-1211.7% operating margin), and net income was -$2.1M, reflecting a -721.7% net profit margin. Diluted earnings per share stood at -$0.08. The company generated $1.9M in operating cash flow. The current ratio was 0.01, measuring current assets divided by current liabilities.
Upcoming Events
QBIO Company Profile & Sector Positioning
Q BIOMED (QBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing QBIO often look at related companies in the same sector, including BIOSTAX CORP (BTAX), SCOPUS BIOPHARMA INC (SCPS), VIRPAX PHARMS INC (VRPX), EVELO BIOSCIENCES INC (EVLO), and PAXMEDICA INC (PXMD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate QBIO's relative position within its industry.